NCT03303313 - A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome | Biotech Hunter

Timeline

Start Date

September 19, 2017

Primary Completion Date

September 12, 2018

Study Completion Date

September 12, 2018

Conditions

Atypical Hemolytic Uremic Syndrome

Interventions

DRUG

Cemdisiran

Subcutaneous (sc) injection of Cemdisiran

Trial Locations (12)

Clinical Trial Site, Sarajevo

Clinical Trial Site, Tallinn

Clinical Trial Site, Tartu

Clinical Trial Site, Tbilisi

Clinical Trial Site, Riga

Clinical Trial Site, Kaunas

Clinical Trial Site, Vilnius

Clinical Trial Site, Chisinau

Clinical Trial Site, Skopje

Clinical Trial Site, Belgrade

Clinical Trial Site, Örebro

Clinical Trial Site, Calgary